People, Not Products, are the Future of Banking, Finds Economist Intelligence Unit Report for Temenos
30.9.2021 09:30:00 EEST | Business Wire | Press release
A new report by the Economist Intelligence Unit published today by Temenos (SIX:TEMN), the banking software company, reveals that four in five bankers (81%) believe that financial institutions will seek to differentiate themselves on customer experience rather than on their products and services in the next four years. The report underscores the importance of customer experience, as changes to customer banking behavior triggered by the pandemic create long-term structural changes.
The report, titled “Demanding More”, is based on a recent global survey of 305 senior banking executives conducted by the Economist Intelligence Unit (EIU). The report highlights how financial institutions have been forced to adapt to the sudden movement of customers managing their finances online, which has proved beneficial to digital-only banks. As an example, as of January 2021, 14 million British citizens (27% of UK adults) had a digital-only bank account, representing a 16% growth from January 2020 and an increase of 3X compared to January 2019. Almost three in four (71%) global respondents expect cash to represent less than 5% of all retail transactions globally by 2025.
The shift towards online banking has highlighted the evolution of how financial institutions manage relationships and the demise of the traditional branch. Global banking executives’ top strategic priorities are all customer-focused. Improving customer experience and engagement, including personalization and intimacy, was viewed as the top strategic priority by 30%.
The report further reveals that consumers, particularly Millennials and Gen Z, are increasingly demanding that companies follow responsible business practices. This is leading to business engagement with issues that are important to consumers, such as combating climate change and promoting diversity and financial inclusion. Additionally, banking executives are prioritizing the financial empowerment of their customers. Findings show that around one in three financial institutions are considering growing microfinance for entrepreneurs (34%), deposits for unbanked populations (33%) and responsible lending to under-banked populations (32%) in the next one to three years.
Joaquin de Valenzuela Muley, SVP & Busines Line Director – Temenos Infinity, said: “Banking is a very human experience, and yet for so many, banking doesn’t happen the way we live our lives. In today’s world, the relationship financial institutions have with members or customers is more critical than ever. Banks are moving their customers from physical into digital channels and the winners will be those who can inject intimacy into those channels. Banks will need to provide a digitally-driven customer experience in assisted channels and online – offering advice, value-added services, and ‘always on’ banking, helping individuals, families, and businesses to meet their dreams and aspirations. This report showcases what should have already been obvious: banking is about the people, and the products need to reflect that.”
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005613/en/
Contact information
Media Contacts
Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email: press@temenos.com
Alistair Kellie / Ian Morris / Matt Redley / George Esmond
SEC Newgate on behalf of Temenos
Tel: +44 20 7680 6550
Email: AllNewgateTemenos@secnewgate.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vasion Output ™ from Vasion Achieves SAP ® Certified Integration with GROW for SAP and with RISE with S/4HANA ® Cloud24.2.2026 15:00:00 EET | Press release
Vasion, a leader in serverless printing and Intelligent Print Automation, today announced that Vasion Output has achieved SAP® certification as integrated with GROW with SAP and integrated with RISE with SAP S/4HANA® Cloud. The Vasion solution is purpose-built to eliminate legacy output management as a cloud migration barrier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224741412/en/ Chee Tan, Vice President of Ecosystem & Alliances at Vasion, leads Vasion’s global strategic ecosystem partnerships. He drives the integration of AI-powered output management and document workflows with leading enterprise solutions such as SAP S/4HANA, enabling organizations to modernize print infrastructure, consolidate environments, and automate enterprise document workflows. The certification confirms what enterprise resource planning (ERP) customers moving to S/4HANA need most: proven infrastructure that handles mission-critical docume
NorthX Biologics and Demeetra Announce Strategic Collaboration to Deliver a Faster, Lower-Risk Path from Gene to GMP24.2.2026 15:00:00 EET | Press release
NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom to operate and no additional IP-related costs, together with advanced cell line development technologies and high-quality process development, MCB banking, and GMP manufacturing services. The collaboration is designed to help biotech companies reach IND-enabling and clinical milestones faster, with fewer technical setbacks and without the need to rebuild cell lines or re-qualify processes when transitioning to a manufacturing partner. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224427714/en/ Supporting stable, high-titer cell line development and seamless GMP advancement. The partnership combines Demeetra’s CleanCut™ CHO platforms and stable CLD services with NorthX Biologics’ proven GMP production capabilities, process scale-up expertise including fill and finish, and re
ExaGrid Wins New Industry Award24.2.2026 15:00:00 EET | Press release
ExaGrid®, the leader in Tiered Backup Storage, today announced that it has been honored with an award in the Secondary Storage category from the first annual StorageNewsletter Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224387048/en/ ExaGrid Tiered Backup Storage wins the award for Secondary Storage for the first annual StorageNewsletter Awards. The winners of the StorageNewsletter Awards were chosen by a seven-member jury who selected the vendors for each category. “A long-standing innovator, ExaGrid has played a key role in shaping a new era of secondary storage with its scale-out architecture. Originally built around HDDs, the platform now supports SSDs and continues to gain market share at a rapid pace, driven by a strong channel ecosystem and broad validation from numerous backup software vendors. Through continuous feature enhancements, the team has led this segment for many years, and the outlook for fut
Axelera AI Secures More Than $250 Million Funding on Global Commercial Growth24.2.2026 15:00:00 EET | Press release
Axelera AI, the European leader in AI acceleration hardware, announced its latest funding round led by Innovation Industries, with participation from prominent funds and accounts including BlackRock and SiteGround Capital as new investors, as well as existing investors Bitfury, CDP Venture Capital, European Innovation Council Fund, Federal Holding and Investment Company of Belgium (SFPIM), Invest-NL, Samsung Catalyst Fund, and Verve Investments. Axelera AI has attracted over $450 million in equity, grants and venture debt since incorporating in July 2021. The largest investment ever in an EU AI semiconductor company comes as Axelera ships to its 500th global customer across physical AI and edge AI in industries including defense and public safety, industrial manufacturing, retail, agritech, robotics, and security, firmly establishing the company as the global leader in power-efficient AI inference solutions. Axelera AI’s success is rooted in a fundamental insight: to deploy AI at scale
AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 202624.2.2026 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA. The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative design is supported by the Phase 1b dose escalation results, which showed encouraging safety and promising anti-tumor activity of ADVC001. At the recommended Phase 2 dose, 80% of patients achieved a 50% reducti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
